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History
The bisphosphonates, in the past erroneously called
diphosphonates, have been known to chemists since the
middle of the 19th century, the first synthesis dating back
to 1865 in Germany [1]. Their use was industrial (mainly in
the textile, fertilizer and oil industries) and, because of their
property of inhibiting calcium carbonate precipitation, as
preventors of scaling. Our knowledge of the biological
characteristics of bisphosphonates dates back 30 years,
the first report about them, actually by the present author’s
group, having been presented in 1968 [2]. The concept
was derived from earlier studies in our laboratory on inor-
ganic pyrophosphate [3], in which it was found that
plasma and urine contained compounds inhibiting calcium
phosphate precipitation in vitro and it was found that part
of this activity was due to inorganic pyrophosphate, a sub-
stance that had not been described previously in these
fluids. We then found that pyrophosphate also inhibited
calcium phosphate dissolution in vitro. In vivo, this com-
pound prevented ectopic calcification but had no effect on
normal mineralization and on bone resorption, possibly
because it was destroyed locally by phosphatases. This
prompted us to look for analogs of pyrophosphate that
were not destroyed enzymatically. The bisphosphonates
fulfilled these conditions [4,5].
Chemistry
Bisphosphonates are compounds characterized by two
C–P bonds. If the two bonds are located on the same
carbon atom the compounds are called geminal bisphos-
phonates (although usually just bisphosphonates), and
they are analogs of pyrophosphate that contain an oxygen
atom instead of a carbon atom (Figs 1 and 2 show two
bisphosphonates used in tumor bone disease).
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Abstract
Bisphosphonates are synthetic compounds characterized by a P–C–P group, and are thus analogs of
inorganic pyrophosphate. They are used in medicine mainly to inhibit bone resorption in diseases like
osteoporosis, Paget’s disease and tumor bone disease. They have been used for over a century in
industry, and only in 1968 was it shown that bisphosphonates have biological effects. These effects
consist mainly of an inhibition of bone resorption and, when given in large amounts, an inhibition of
ectopic and normal calcification. While the latter effect is the consequence of a physical–chemical
inhibition of calcium phosphate crystal formation, the former is due to a cellular effect involving both
apoptosis of the osteoclasts and a destruction of the osteoclastic cytoskeleton, inducing a decrease in
osteoclast activity. The biochemical basis of these effects for the nitrogen-containing compounds is an
inhibition of the mevalonate pathway caused by the inhibition of farnesylpyrophosphate synthase,
which leads to a decrease of the formation of isoprenoid lipids such as farnesylpyrophosphate and
geranylgeranylpyrophosphate. The other bisphosphonates are incorporated into the phosphate chain
of ATP-containing compounds so that they become non-hydrolyzable. The new P–C–P-containing ATP
analogs inhibit cell function and may lead to apoptosis and death of osteoclasts.
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The P–C–P structure allows a great number of possible
variations, mostly by changing the two lateral chains on
the carbon. Small changes in the structure of the bisphos-
phonates can lead to extensive alterations in their physico-
chemical, biological, therapeutic, and toxicological
characteristics. Many bisphosphonates have been investi-
gated in humans with respect to their effects on bone, and
eight of them are commercially available today for treat-
ment of bone disease.
Physicochemical effects
As is the case for pyrophosphate, most of the bisphospho-
nates inhibit the precipitation of calcium phosphate even
at very low concentration [4]. Bisphosphonates also slow
down the dissolution of these crystals [5]. All these effects
appear to be related to the marked affinity of these com-
pounds for the solid-phase calcium phosphate to which
they bind [6].
Effect on bone resorption
The fact that bisphosphonates inhibit calcium phosphate
crystal dissolution in vitro led us to hypothesize that these
compounds might also act on bone resorption in vivo. The
hypothesis of an effect on bone destruction proved
correct, but the mechanism of action is different from that
originally conceived.
In vitro, bisphosphonates decrease the destruction of bone
in embryonic long bones and in neonatal calvaria [5]. An inhi-
bition can also be found when the effect of isolated osteo-
clasts is investigated on various mineralized matrices in vitro.
In vivo, bisphosphonates inhibit bone resorption both in
normal animals as well as in animals in which bone resorp-
tion is stimulated experimentally, for example with parathy-
roid hormone [5], retinoids and others. Thus, in growing
rats, bisphosphonates block the degradation of both bone
and cartilage, and thus arrest the remodeling of the meta-
physis, which becomes club shaped and radiologically
more dense than normal [7]. The decrease in resorption is
accompanied by an increase in both the calcium balance
[8] and the mineral content of the bone.
Bisphosphonates prevent bone loss in many experimental
diseases. This is the case for various osteoporosis
models, such as limb immobilization, ovariectomy,
orchidectomy, corticosteroid administration, and other
models. Their effect is accompanied by an improvement of
the biomechanical properties of bone.
As regards tumor bone resorption, bisphosphonates very
effectively inhibit tumoral bone resorption both in vitro and
in vivo. In vitro, they inhibit the bone resorbing effect of
supernatants of various cancers in mice calvaria [9]. In
vivo, both the hypercalcemia induced by the tumor [10]
and the development of the metastases [11] are dimin-
ished. The inhibited development of metastases can have
various causes. One of these is that, because less bone is
destroyed, the area for tumoral expansion is limited.
Another explanation involves the self-supporting cycle
called the ‘seed and soil mechanism’ by which growth
factors present in bone, such as transforming growth
factor-β and insulin-like growth factors, are liberated
during bone resorption and thereafter stimulate the multi-
plication of tumor cells. As a consequence of a decrease
in bone resorption, this cycle would be interrupted [12].
Furthermore, bisphosphonates can inhibit the adhesion of
tumor cells to mineralized matrices in vitro, both when the
cells or the matrix are treated [13,14]. Finally, there is now
evidence that bisphosphonates can decrease multiplica-
tion of tumor cells in vitro and can also induce their apop-
tosis by inhibiting the mevalonate pathway (Fig. 3) [15].
Relative activity of bisphosphonates on bone
resorption
The activity of bisphosphonates on bone resorption varies
greatly from compound to compound. For etidronate, the
first bisphosphonate to be investigated with clodronate,
the dose required to inhibit resorption is relatively high (in
the rat, greater then 1 mg/kg parenterally per day). Since
this dose is near that which impairs normal mineralization,
Figure 1
Chemical structure of clodronate.
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one of the aims of bisphosphonate research has been to
develop compounds with a more powerful antiresorptive
activity but without a higher inhibition of mineralization.
Today, compounds have been developed that are
1–10,000 times more powerful inhibitors than etidronate
in inhibiting bone resorption, without a large difference in
the inhibition of mineralization.
Structure–activity relationship for bone
resorption
The length of the aliphatic carbon chain is important, and
adding a hydroxyl group to the carbon atom at position 1
increases potency. Derivatives with an amino group at the
end of the side chain are very active. The length of the
side chain is again relevant; the highest activity being
found with a backbone of four carbons, as present in alen-
dronate. A primary amine is not necessary for this activity
since dimethylation of the amino nitrogen of pamidronate,
as seen in olpadronate, increases efficacy. Activity is still
further increased when other groups are added to the
nitrogen, as seen in ibandronate. Cyclic geminal bisphos-
phonates are also very potent, especially those containing
a nitrogen atom in the ring, such as risedronate. The most
active compounds described so far, zoledronate and min-
odronate, belong to this class of cyclic bisphosphonates.
Mechanisms of action in inhibiting bone
resorption
Our understanding of the mode of action of the bisphos-
phonates has made great progress in the past few years.
There is no doubt that the action in vivo is mediated
mainly, if not completely, through mechanisms other than
the physicochemical inhibition of crystal dissolution, as
was initially postulated. These mechanisms are, according
to all available data, cellular. Many of these mechanisms
have been unraveled and it may well be that several mech-
anisms are operating simultaneously.
The fact that the bisphosphonates act almost exclusively
on bone when administered at physiological doses occurs
because they have a special affinity to this tissue, where
they deposit both in newly formed bone and under the
osteoclasts [16]. The action on the osteoclast involves
various processes: inhibition of osteoclast recruitment,
shortening of the life span of osteoclasts because of pro-
grammed cell death (apoptosis) [17], and inhibition of
osteoclast activity. The effect on the osteoclasts leads to a
decrease in bone turnover that is secondary to the inhibi-
tion of bone resorption.
At the molecular level, a great number of biochemical
effects have been described over the years. A decrease of
acid production, possibly sometimes by inhibiting the
osteoclast vacuolar H+-ATPase, an inhibition of lysosomal
enzymes, an inhibition of prostaglandin synthesis, an inhi-
bition of protein-tyrosine phosphatases, and an inhibition
of matrix metalloproteinases are some examples of these
effects. Unfortunately, from the many mechanisms, no
single one shows a stringent correlation with the inhibition
of bone resorption in vivo when different bisphosphonates
of various potencies are investigated.
Some new findings have very recently changed the
picture. Nitrogen-containing bisphosphonates were found
to inhibit the mevalonate pathway [18,19], by inhibiting far-
nesylpyrophosphate synthase [20,21]. This inhibition
leads to a decrease of the formation of isoprenoid lipids
such as farnesylpyrophosphate and geranylgeranyl-
pyrophosphate. These are required for the post-transla-
tional prenylation (transfer of long-chain isoprenoid lipids)
of proteins, including the GTP-binding proteins Ras, Rho,
Rac, and Rab. These proteins are important for many cell
functions. Disruption of their activity will induce a series of
changes leading to decreased activity, probably the main
effect, and to induction of cell death by apoptosis in
several cell types, including osteoclasts. The lack of ger-
anylgeranylpyrophosphate in osteoclasts is most probably
responsible for these effects [22,23]. Of considerable
interest is the fact that, when various bisphosphonates of
various potencies to inhibit bone resorption were investi-
gated, their effect on the mevalonate pathway corre-
sponded well to that of inhibiting bone resorption [24].
Nitrogen-containing bisphosphonates also block cell
growth in vitro of normal human epidermal keratinocytes,
used as a model for esophageal irritation, without inducing
apoptosis, as seen in osteoclasts [25]. The doses of bis-
phosphonates inhibiting cell growth also inhibited geranyl-
geranylation and farnesylation [25]. These results suggest
that the basic mechanism of action is similar both in osteo-
clasts and in the gastrointestinal mucosa.
Figure 3
Effect of nitrogen-containing bisphosphonates on the mevalonate
pathway by inhibiting farnesylpyrophosphate synthase. HMG-CoA,
hydroxymethylglutaryl-coenzyme A; PP, pyrophosphate. Reproduced
with permission from Fleisch [28].
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Geranylgeranylated proteinsFurthermore, it was shown that some non-nitrogen-
containing bisphosphonates closely resembling pyrophos-
phate, such as etidronate, tiludronate and clodronate, do
not act through this pathway. These compounds are incor-
porated into the phosphate chain of ATP-containing com-
pounds so that they become non-hydrolyzable. The new
P–C–P-containing ATP analogs inhibit cell function and
may lead to apoptosis and cell death [26,27].
The bisphosphonates can thus be classified into two
major groups with different modes of action.
Effect on calcification
Bisphosphonates prevent experimentally induced calcifica-
tion of many soft tissues, including among others arteries,
kidneys, and skin, both when given parenterally and orally
[4]. If administered at a sufficient dose, certain bisphospho-
nates (such as etidronate) can also impair the mineralization
of normal calcified tissues such as bone [7] and cartilage
[7], as well as dentine, enamel and cementum. The inhibi-
tion is eventually reversed after discontinuation of the drug.
The inhibition of ectopic mineralization is most probably
due chiefly to the physicochemical inhibition of crystal
growth, although at least some effect on the matrix cannot
be totally excluded.
Clinical uses
Bisphosphonates are used clinically as skeletal markers in
the form of 99mTc derivatives, antiosteolytic agents in patients
with increased bone destruction, and inhibitors of calcifica-
tion in patients with ectopic calcification and ossification. The
most common use of bisphosphonates is in diseases with
increased bone resorption such as Paget’s disease, osteo-
porosis and tumor bone disease (for a review, see [28]).
Bisphosphonates are now the therapy of choice in Paget’s
disease. The compound most often used was, and possi-
bly still is, pamidronate, given parenterally. The bisphos-
phonates decrease bone turnover, often to normal values,
they improve the morphology of bone, and they ameliorate
bone pain. The effect often persists over a long time after
discontinuation of the treatment.
Various bisphosphonates have been investigated in osteo-
porosis, the compounds investigated most thoroughly
being alendronate and risedronate. The bisphosphonates
not only inhibit bone loss, but can actually also increase
bone mineral density. Furthermore, the vertebral and non-
vertebral fracture incidence is decreased by about one-
half. Bisphosphonates are active in, among others,
postmenopausal and elderly women, in men, and in corti-
costeroid-treated patients.
Finally, bisphosphonates are the drugs of choice to
decrease bone resorption in tumor bone disease, the most
common being pamidronate and clodronate. The therapy
induces a diminution of bone resorption, leading to a
decrease in hypercalcemia, a decrease of new osteolytic
lesions and a decrease of fractures, and leading to an ame-
lioration of pain and an improvement of the quality of life.
For further information on preclinical and clinical aspects
of bisphosphonates, a book [28] and various recent
reviews [29,30] are available.
References
1. Menschutkin M: Ueber die Einwirkung des Chloracetyls auf
phosphorige Säure. Ann Chem Pharm 1865, 133:317-320.
2. Fleisch H, Russell RGG, Bisaz S, Casey P, Mühlbauer R: The
influence of pyrophsophate analogues (diphosphonates) on
the precipitation and dissolution of calcium phosphate in vitro
and in vivo. Calcif Tissue Res 1968, 2(suppl):10-10a.
3. Fleisch H, Russell RGG, Straumann F: Effect of pyrophosphate
on hydroxyapatite and its implications in calcium homeosta-
sis. Nature (London) 1966, 212:901-903.
4. Francis MD, Russell RGG, Fleisch H: Diphosphonates inhibit
formation of calcium phosphate crystals in vitro and patho-
logical calcification in vivo. Science 1969, 165:1264-1266.
5. Fleisch H, Russell RGG, Francis MD: Diphosphonates inhibit
hydroxyapatite dissolution in vitro and bone resorption in
tissue culture and in vivo. Science 1969, 165:1262-1264.
6. Jung A, Bisaz S, Fleisch H: The binding of pyrophosphate and
two diphosphonates by hydroxyapatite crystals. Calcif Tissue
Res 1973, 11:269-280.
7. Schenk R, Merz WA, Mühlbauer R, Russell RGG, Fleisch H:
Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and
dichloromethylene diphosphonate (Cl2MDP) on the
calcification and resorption of cartilage and bone in the tibial
epiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:
196-214.
8. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ: The influence
of two diphosphonates on calcium metabolism in the rat. Clin
Sci 1972, 43:31-45.
9. Jung A, Mermillod B, Barras C, Baud M, Courvoisier B: Inhibition
by two diphosphonates of bone lysis in tumor conditioned
media. Cancer Res 1981, 41:3233-3237.
10. Martodam RR, Thornton KS, Sica DA, d’Souza F, Flora L, Mundy
GR:  The effects of dichloromethylene diphosphonate on
hypercalcemia and other parameters of the humoral hyper-
calcemia of malignancy in the rat Leydig cell tumor. Calcif
Tissue Int 1983, 35:512-519.
11. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce, R,
Mundy GR, Yoneda T: Bisphosphonate risedronate reduces
metastatic human breast cancer burden in bone in nude mice.
Cancer Res 1995, 55:3551-3557.
12. Mundy GR, Yoneda T. Facilitation and suppression of bone
metastasis. Clin Orthop Relat Res 1995, 312:34-44.
13. van der Pluijm G, Vloedraven H, van Beek E, van der Wee-Pals L,
Löwik C, Papapoulos S: Bisphosphonates inhibit the adhesion
of breast cancer cells to bone matrices in vitro. J Clin Invest
1996, 98:698-705.
14. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas
PD, Clezardin P: Bisphosphonates inhibit prostate and breast
carcinoma cell adhesion to unmineralized and mineralized
bone extracellular matrices. Cancer Res 1997, 57:3890-3894.
15. Shipman CM, Croucher PI, Russell RGG, Hlfrich MH, Rogers MJ:
The bisphosphonate incadronate (YM175) causes apoptosis
of human myeloma cells in vitro by inhibiting the mevalonate
pathway. Cancer Res 1998, 58:5294-5297.
16. Masarachia P, Weinreb M, Balena R, Rodan GA: Comparison of
the distribution of 3H-alendronate and 3H-etidronate in rat and
mouse bones. Bone 1996, 19:281-290.
17. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman
GD, Mundy GR, Boyce BF: Bisphosphonates promote apopto-
sis in murine osteoclasts in vitro and in vivo. J Bone Miner Res
1995, 10:1478-1487.
18. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MG:
Heterocycle-containing bisphosphonates cause apoptosis
Available online http://breast-cancer-research.com/content/4/1/030
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
eBreast Cancer Research    Vol 4 No 1 Fleisch
and inhibit bone resorption by preventing protein prenylation:
evidence from structure–activity relationships in J774
macrophages. J Bone Miner Res 1998, 13:1668-1678.
19. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MG:
Nitrogen-containing bisphosphonates inhibit the mevalonate
pathway and prevent post-translational prenylation of gtp-
binding proteins, including ras. J Bone Miner Res 1998, 13:
581-589.
20. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S: Far-
nesyl pyrophosphate synthase is the molecular target of
nitrogen-containing bisphosphonates. Biochem Biophys Res
Commun 1999, 264:108-111.
21. Bergstrom JD, Bostedor RG, Masarachia PJ, Rewszka AA, Rodan
GA: Alendronate is a specific, nanomolar inhibitor of farnesyl
diphosphate synthase. Arch Biochem Biophys 2000, 373:231-
241.
22. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DF,
Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka
AA:  Alendronate mechanism of action: gernylgeraniol, an
intermediate in the mevalonate pathway, prevents inhibition
of osteoclast formation, bone resorption, and kinase activa-
tion in vitro. Proc Natl Acad Sci 1999, 96:133-138.
23. van Beek E, Löwik C, van der Pluijm G, Papapoulos S: The role
of geranylgeranylation in bone resorption and its suppression
by bisphosphonates in fetal bone explants in vitro: a clue to
the mechanism of action of nitrogen-containing bisphospho-
nates. J Bone Miner Res 1999, 14:722-729.
24. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM,
Poulter CD, Ebetino FH, Rogers MJ: Strucuture–activity rela-
tionships for inhibition of farnesy diphosphate synthase in
vitro and inhibition of bone resorption in vivo by nitrogen-con-
taining bisphosphonates. J Pharmacol Exper Ther 2001,
296:235-242.
25. Reszka AA, Halasy-Nagy J, Rodan GA: Nitrogen-bisphospho-
nates block retinoblastoma phosphorylation and cell growth
by inhibiting the cholesterol biosynthetic pathway in a ker-
atinocyte model for esophageal irritation. Mol Pharmacol
2001, 59:193-202.
26. Rogers MJ, Brown RG, Hodkin V, Russell RGG, Watts DJ: Bis-
phosphonates are incorporated into adenine nucleotides by
human aminoacyl-trna synthetase enzymes. Biochem Biophys
Res Commun 1996, 224:863-869.
27. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ:
Clodronate and liposome-encapsulated clodronate are
metabolised to a toxic ATP analog, adenosine 5′ ′(β β,γ γ-
dichloromethylene)triphosphate, by mammalian cells in vitro.
J Bone Miner Res 1997, 12:1358-1367.
28. Fleisch H: Bisphosphonates in Bone Disease. From the Labora-
tory to the Patient. New York: Academic Press; 2000.
29. Fleisch H: Bisphosphonates: mechanisms of action. Endocr
Rev 1998, 19:80-100.
30. Russell RGG, Croucher PI, Rogers MJ: Bisphosphonates: phar-
macology, mechanisms of action and clinical uses. Osteo-
poros Int 1999, 2(suppl):s66-s80.